Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BNZ132-1-40 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| BNZ-1 | EXPERIMENTAL | IV PEGylated BNZ132-1-40 |
| Placebo | PLACEBO_COMPARATOR | Normal saline |
| BNZ132-1-40 | EXPERIMENTAL | PEGylated BNZ-1 for Injection |
| Name | Type | Description |
|---|---|---|
| BNZ132-1-40 | DRUG | Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15 |
| Placebo | DRUG | Normal Saline |
Inclusion Criteria: * Willing and able to consent and participate in the study. * Agrees not to receive any other investigational product or therapy while participating in this study. * Must be: * Currently using two forms of effective birth control (one of which is a barrier method) for the dur...
BNZ132-1-40 is an investigational monoclonal antibody being studied for use in LGL leukemia and refractory CTCL, as well as for safety and tolerability in healthy subjects. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
BNZ132-1-40 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. It is being investigated for its potential effects in LGL leukemia and refractory CTCL, though the exact mechanism of action is not publicly detailed.
BNZ132-1-40 is being developed by Equillium, Inc., a biopharmaceutical company. Equillium is publicly traded under the ticker symbol EQ on the NASDAQ stock exchange.
BNZ132-1-40 is in Phase 1 clinical development. All three clinical trials for BNZ132-1-40 are Phase 1 studies and have been completed. The drug is investigational and has not received FDA approval.
BNZ132-1-40 has been studied in three completed Phase 1 trials: NCT03046459, a first-in-human study in healthy subjects; NCT03239379, a multiple-dose study in healthy adults; and NCT03239392, a dose-ranging study in patients with LGL leukemia or refractory CTCL.
BNZ132-1-40 is also referred to as BNZ-1 in clinical trial records. The trial NCT03239392, titled 'A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL,' uses the name BNZ-1 to refer to the same investigational drug.